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S U M M A R Y
Objectives: To assess the herpes zoster (HZ) disease burden, including the severity and duration of HZ-
associated pain, its impact on quality of life (QoL), and healthcare resource utilization (HCRU) in a South
Korean clinical setting.
Methods: Patients aged 50 years were followed prospectively for 6 months. Based on the duration of
their episode at enrolment, cases were classiﬁed as incident (<7 days) or prevalent (7 days). HZ pain
and discomfort were measured with the HZ Severity of Illness (HZ-SOI) severity-by-duration composite
score.
Results: One hundred ﬁfty-one patients (69.5% prevalent cases) were enrolled. Prodrome pain was
experienced by 68.2% of patients, of whom 95.1% experienced moderate-to-severe pain; post-herpetic
neuralgia was experienced by 38.4%. Prevalent disease, higher acute pain, and older age were signiﬁcant
predictors of greater HZ-SOI, while use of antivirals was associated with decreased HZ-SOI. HZ-
associated pain was associated with reduced QoL and affected all daily living activities (particularly
mood, life enjoyment, general activities, and sleep), resulting in signiﬁcant HCRU, including primary care
doctor, specialist, or physiotherapist consultations, hospitalizations, and emergency department visits.
Conclusion: Severe morbidity, impaired QoL, and signiﬁcant HCRU are associated with HZ in South
Korea, especially in older patients, supporting the need for early intervention and preventive strategies
to reduce the HZ-associated disease burden.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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In South Korea, the disease burden of herpes zoster (HZ),
commonly known as shingles or zoster, has been considerably
higher than that reported for other countries and has been
increasing in the last 5 years; this increase could be related to an
increase in longevity.1 Adults and the elderly in particular are likely
to suffer the debilitating effects and considerable levels of pain
caused by the reactivation of varicella zoster virus (VZV), which, as
a primary infection, produces chickenpox.2–7ociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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vesicular, cutaneous eruption with a dermatomal distribution,4,7,3
the most frequently debilitating symptom is pain, which may
occur during the prodromal phase, the acute eruptive phase, and
the post-herpetic phase of the infection. Zoster-associated pain
may persist for months or even years after the rash has healed,8–11
diminishing the patient’s quality of life (QoL) and functional
capacity to a degree comparable to that in diseases such as
congestive heart failure, myocardial infarction, diabetes mellitus
type 2, and major depression.4
Despite the availability of a plethora of antiviral and other
medications, it is difﬁcult to adequately treat HZ and post-herpetic
neuralgia. According to the guidelines of the International Herpes
Management Forum, treatment with oral antiviral agents for 7 days
is recommended for patients at risk of developing post-herpetic
neuralgia (>50 years of age, severe acute pain, severe rash, or
signiﬁcant prodromal symptoms).12 However, to be maximally
effective, antiviral agents should be administered within 72 h of
acute symptom onset, which is often not possible due to delays in
patients seeking medical help or to delayed diagnosis.12–14
Furthermore, even if timely therapy takes place, current treatments
are effective in some patients, but may show limited beneﬁt and
poor tolerability in others,15 especially those already taking other
medications. Although treatment with antiviral agents accelerates
cessation of viral shedding, hastens rash healing, and reduces the
duration of acute pain,16 a recent Cochrane review concluded that
treatment with oral aciclovir does not have a signiﬁcant impact on
the incidence of post-herpetic neuralgia.17 Similarly, another meta-
analysis concluded that oral corticosteroids given acutely during HZ
reactivation are ineffective in preventing post-herpetic neuralgia.18
Recently, a vaccine against HZ was shown to reduce the HZ burden of
illness by 61%, the incidence of post-herpetic neuralgia by 67%, and
the incidence of HZ by 51%19 in adults 60 years of age and older.
Similarly, the recent Zostavax Efﬁcacy and Safety Trial (ZEST)
showed that zoster vaccination in patients aged between 50 and 59
years signiﬁcantly reduces the incidence of HZ by 70%.20 As such,
these studies have demonstrated the efﬁcacy of a zoster vaccine in
signiﬁcantly decreasing both the incidence and severity of HZ and
post-herpetic neuralgia among older adults.
To date, data on the burden of HZ speciﬁc to South Korea are
scarce.1 The purpose of this prospective observational study was to
measure the burden of illness due to HZ and post-herpetic
neuralgia, assess their impact on QoL, and determine the
associated healthcare resource utilization (HCRU) in South Korea.
In addition to providing evidence of the medical need, the current
study was done to inform the evidence-based decision-making
process related to future vaccination policies in South Korea.
2. Methods
2.1. Study design
This study followed similar methods to those described in the
MASTER (Monitoring and Assessing Shingles Through Education
and Research) set of studies.21 This was a 6-month, prospective,
observational study in HZ patients recruited from the practices of
19 specialists (three infectious diseases specialists and 16
dermatologists) from the Korea University Guro Hospital (six
investigators), the Kyung Hee University Medical Center (ﬁve
investigators), and the Catholic University of Korea (eight
investigators) between February 2009 and October 2010. The
study was approved by the institutional review boards of the Korea
University Guro Hospital, the Kyung Hee University Hospital, and
the Catholic Medical Center (CMC) Clinical Research Coordination
Center of the Catholic University of Korea. At recruitment, patients
were assessed for eligibility and underwent a review of historicalexposure to varicella, immune status, HZ characteristics, as well as
a review of HZ medication and treatment use. Incident cases were
deﬁned as patients with a current HZ episode enrolled <7 days
since rash onset or start of zoster-associated pain. Prevalent cases
were deﬁned as patients with a current HZ episode enrolled 7
days after rash onset or start of zoster-associated pain. For the
incident cases, the baseline (day 0) and day 7 assessments were
conducted in the physician’s ofﬁce, while the remaining eight
assessments were conducted through telephone interview on days
14, 21, 30, 60, 90, 120, 150, and 180. For the prevalent cases, the
baseline assessment took place in the physician’s ofﬁce and six
follow-up assessments were completed by telephone interview at
30-day intervals for a total of 6 months.
2.2. Patient population
Male and female patients aged 50 years at the date of onset of
HZ rash, with a physician-conﬁrmed diagnosis of HZ, were eligible
for the study. Additional inclusion criteria were: documented date
of onset of HZ rash in the patient’s chart and the ability to
understand spoken and written Korean, to complete the study
questionnaires, and to understand the study and the content of the
informed consent form, as well as patient availability for the study
follow-up period. Eligible patients provided informed consent
prior to study enrolment.
2.3. Outcome measures
2.3.1. Pain measurements
The primary outcome was the burden of illness due to zoster-
associated pain. This was measured with the HZ Severity of Illness
score (HZ-SOI), a severity-by-duration composite measure of total
pain and discomfort experienced by HZ patients. Pain severity was
derived from the pain ratings obtained from the ‘worst pain in the
last 24 h’ question of the Zoster Brief Pain Inventory (ZBPI).22
The Initial Zoster Impact Questionnaire (IZIQ) was used at the
baseline visit to assess the worst pain during the prodrome phase.
Post-herpetic neuralgia was deﬁned as a score of 3 in the ‘worst
pain in the last 24 h’ question of the ZBPI at 90 days after rash
onset.
2.4. QoL measurements
QoL was measured with the EuroQoL (EQ-5D),23 which
measures ﬁve dimensions, speciﬁcally mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. The EQ-5D has
high validity and has demonstrated reliability across several health
states. At the ﬁrst visit, the EuroQoL questionnaire was completed
by the patient twice to describe: (1) usual QoL without HZ or
zoster-associated pain; (2) QoL in their current health state during
their HZ episode. At each follow-up assessment, the EuroQoL
questionnaire was completed once by the patient.
QoL weighting was used to adjust population-speciﬁc prefer-
ences for the health states deﬁned by the EQ-5D. For the purposes
of this study the Japan-speciﬁc weights, which are more
representative of Asian populations, were used.
2.4.1. Healthcare resource utilization (HCRU)
HCRU was assessed by a simple questionnaire administered at
each follow-up assessment. Patients were asked to record the HCRU
related to their HZ rash or zoster-associated pain. HCRU included
visits to physicians or clinics, hospitalizations, use of other health-
related services including physiotherapy, nursing services, psychol-
ogists, rehabilitation, natural or alternative medicine, prescription
medications, and over-the-counter medications, as well as diagnos-
tic tests and procedures performed. Emphasis was placed on the use
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of HZ episode medications and treatments used was conducted.
During the study follow-up, the zoster-related medication and
treatment inventory was collected to obtain details, including type
and estimated duration of HZ medications and treatments used.
These included prescription medications, over-the-counter pro-
ducts, and other services used.
2.5. Statistical methods
Descriptive statistics were produced for all variables in the study.
Measures of central tendency (mean) and dispersion (standard
deviation (SD), 95% conﬁdence interval) were produced for all
continuous scale variables. Frequency distributions were produced
forall categorical scale variables. In addition tothe totalstudy cohort,
all analyses were stratiﬁed by prevalent and incident HZ cases.Table 1
Patient demographics and baseline characteristics
Demographics and baseline characteristics Cohor
Preva
(n = 10
Age, years, mean (SD) 64.1 (
Female gender, n (%) 60 (57
Days since rash onset, mean (SD) 95.4 (
Employment status at baseline
Full time 29 (27
Part time 6 (5.
Retired 10 (9.
Unemployed 23 (21
Home maker 33 (31
Student 0 (0.
Other 4 (3.
Highest level of education, n (%)
Primary/grade school 21 (20
High school or equivalent 51 (48
Community college 4 (3.
University or higher 10 (9.
No education 12 (11
Missing 7 (6.
HZ primary dermatome region, n (%)
Thoracic 34 (32
Head 20 (19
Lumbar 10 (9.
Cervical 12 (11
Sacral 0 (0.
Missing 29 (27
Ongoing HZ treatment, n (%)a
NSAID or aspirin 57 (54
Topicals 49 (46
Antiviral medications 35 (33
Aciclovir 6 (5.
Famciclovir 21 (20
Valaciclovir 8 (7.
Anti-depressants 38 (36
Anti-epileptics 44 (41
Acetaminophen 42 (40
Opiates 19 (18
Anxiolytics 14 (13
Antibiotics 12 (11
Ophthalmologics 3 (2.
Steroids 3 (2.
Other 27 (25
Worst pain during prodrome phase, VAS cm,b mean (SD) 5.45
Worst pain score, n (%)
3 70 (66
5 62 (59
SD, standard deviation; HZ, herpes zoster; NSAID, non-steroidal anti-inﬂammatory dru
a A patient may have initiated more than one HZ treatment at baseline. Each patient wa
patients in the study (N = 151) or on the respective incident (n = 46) and prevalent (n =
b Worst pain during the prodrome phase was assessed with the Initial Zoster Impact Q
bad as you can imagine). Information was missing for one incident case.For the assessment of the HZ-SOI during the study period, the area
under the curve of worst pain severity over time after enrolment was
calculated using the multiple segment trapezoidal rule for integra-
tion. To adjust for possible confounders, mixed models with repeated
measures were used, where HZ-SOI throughout the follow-up period
was the dependent variable and baseline characteristics were
included as covariates. Mixed effects models assume both popula-
tion characteristics (ﬁxed effects) and individual-speciﬁc effects
(random effects) and accommodate varying follow-up times with
possible missing values. Covariates considered in the model were
visit number, worst pain at baseline, age, immune status (impaired
vs. normal), use of HZ medications, and total number of lesions in the
primary and adjacent dermatomes. Impaired immune status was
deﬁned as the use of oral corticosteroids, immunosuppressive
therapy, therapy for organ transplant, or chemotherapy for solid
tumor, the presence of invasive cancer, HIV/AIDS infections, or at Total cohort
(n = 151)
lent cases
5)
Incident cases
(n = 46)
8.2) 62.7 (9.3) 63.6 (8.5)
.1) 33 (71.1) 93 (61.6)
323.4) 4.2 (1.5) 67.6 (272.5)
.6) 11 (23.9) 40 (26.5)
7) 1 (2.2) 7 (4.6)
5) 3 (6.5) 13 (8.6)
.9) 9 (19.6) 32 (21.2)
.4) 20 (43.5) 53 (35.1)
0) 0 (0.0) 0 (0.0)
8) 2 (4.3) 6 (4.0)
.0) 9 (19.6) 30 (19.9)
.6) 20 (43.5) 71 (47.0)
8) 3 (6.5) 7 (4.6)
5) 7 (15.2) 17 (11.3)
.4) 6 (13.0) 18 (11.9)
7) 1 (2.2) 8 (5.3)
.4) 25 (54.3) 59 (39.1)
.0) 8 (17.4) 28 (18.5)
5) 7 (15.2) 17 (11.3)
.4) 5 (10.9) 17 (11.3)
0) 1 (2.2) 1 (0.7)
.6) 0 (0.0) 29 (19.2)
.3) 31 (67.4) 88 (58.3)
.7) 32 (69.6) 81 (53.6)
.3) 44 (95.6) 79 (52.3)
7) 13 (28.3) 19 (12.6)
.0) 26 (56.5) 47 (31.1)
6) 5 (10.9) 13 (8.6)
.2) 28 (60.9) 66 (43.7)
.9) 15 (32.6) 59 (39.1)
.0) 14 (30.4) 56 (37.1)
.1) 14 (30.4) 33 (21.9)
.3) 7 (15.2) 21 (13.9)
.4) 5 (10.9) 17 (11.3)
9) 0 (0.0) 3 (2.0)
9) 0 (0.0) 3 (2.0)
.7) 19 (41.3) 46 (30.5)
 (4.13) 4.85 (3.97) 5.27 (4.08)
.7) 28 (60.9) 98 (64.9)
.0) 26 (56.5) 88 (58.3)
g; VAS, visual analog scale.
s counted once per medication type. The percentage is based on the total number of
 105) cohorts.
uestionnaire (IZIQ). The level of pain was rated on a VAS of 0 (no pain) to 10 (pain as
Figure 1. Worst pain in the last 24 h as measured with the Zoster Brief Pain
Inventory (ZBPI) by incident and prevalent cases (HZ-SOI, Herpes Zoster Severity of
Illness; CI, conﬁdence interval).
*Least square mean estimate adjusted for all covariates retained in the model. For
prevalent cases, the covariates retained in the model were the visit number and the
worst pain at baseline. For incident cases, age was also retained. Additional
covariates entered in the model, but not retained due to statistical non-signiﬁcance,
included immune status (normal vs. impaired), use of herpes zoster medications,
and number of lesions in the primary and adjacent dermatomes.
yPrevalent cases did not complete the ZBPI at days 7, 14, and 21. Only one direction
of the 95% CI is shown in the ﬁgure for visual clarity.
H. Song et al. / International Journal of Infectious Diseases 20 (2014) 23–3026hematologic malignancy, or a low neutrophil or CD4 count.
Backward selection of variables with p < 0.05 was used to identify
the covariates to be kept in the ﬁnal model.
Parameters affecting the HZ-SOI since rash onset were assessed
using multiple regression analysis. Considering that each patient
entered the cohort at a different time after rash onset and
contributed to the HZ-SOI after that point, a Markov Chain Monte
Carlo (MCMC) method was used to generate 1000 datasets with
imputed missing values before the predictor assessment. The
robustness of the model was examined by comparing the imputed
and the observed HZ-SOI in patients with complete proﬁles.
Sample-size calculations were based on the precision of the
sample estimates related to the zoster-associated pain severity in
patients still experiencing pain at various time points from HZ rash
onset. Based on the proportion of incident cases in the Canadian
MASTER study,21 the proportion of patients experiencing clinically
signiﬁcant zoster-associated pain at 30, 60, 90, 120, and 180 days
after HZ rash onset,19 and the standard deviation of BPI pain
observed in non-cancer patients as a proxy,24 a sample size of 150
patients would produce a standard error of the mean between
0.23 and 0.45 depending on the study visit. Statistical analyses
were conducted with SPSS 12.0 (SPSS Inc., Chicago, IL, USA) and SAS
9.2 (SAS Institute, Cary, NC, USA).
3. Results
A total of 151 patients were enrolled in the study, of whom 46
(30.5%) were incident HZ cases and 105 (69.5%) were prevalent HZ
cases. Table 1 summarizes the patient characteristics at baseline,
overall and by type of cohort (prevalent vs. incident). The mean (SD)
age was 63.6 (8.5) years and the majority of patients were female
(61.6%). The mean time since rash onset was 67.6 days for the overall
study population, 95.4 days for the prevalent cases, and 4.2 days for the
incident cases. The most common documented primary dermatome
region for HZ was the thoracic region (39.1%), followed by the head
region (18.5%). At study enrolment, 58.3% were treated with a non-
steroidal anti-inﬂammatory (NSAID) or aspirin and 52.3% with a topical
agent, while the use of an antiviral agent was reported by 52.3% of
patients. Pain had been experienced by 68.2% of patients during the
prodromal phase. Of these patients, the vast majority (95.1%) experi-
enced moderate to severe pain (worst pain score 3) during that period.
The intensity of HZ-associated worst pain by patient cohort
over time is shown in Figure 1. Overall, the total HZ burden was
higher in the prevalent cases compared to the incident cases during
the study period. A signiﬁcant (p < 0.001) decrease over time was
observed in the HZ-SOI score in both patient subgroups; however,
the rate of the decrease from peak was higher in the incident cases.
Increased worst pain at baseline was associated with a greater HZ-
SOI (p < 0.01). Furthermore, older age was identiﬁed as a predictor
of greater HZ-SOI in the incident cases (p < 0.001). However,
immune status at baseline, the use of HZ medications, and the
number of lesions in the primary and secondary dermatome(s) did
not have a signiﬁcant impact on HZ-SOI. Post-herpetic neuralgia
was reported in 38.4% of the total cohort: 46.7% of the prevalent
cases and 19.6% of the incident cases.
When assessing the HZ-SOI since rash onset, older age, type of
patient cohort, use of antiviral medications, and worst pain at rash
onset were identiﬁed as signiﬁcant independent predictors
(Table 2). Upon mutual adjustment for all possible predictors,
prevalent cases experienced a signiﬁcantly higher burden of illness
overall and during the acute (0–30 days) and sub-acute (30–90
days) phases. Patients 70 years of age or older also experienced
greater HZ-SOI compared to patients aged between 50 and 59
years. A signiﬁcant association between antiviral medication use
and reduced burden of illness was observed overall and across all
phases of the course of HZ. Finally, increased pain severity at rashonset predicted a greater HZ-SOI during the acute phase, but not
the sub-acute and chronic phases.
Table 3 summarizes the mean severity of least, average, and
current pain over time as assessed with the ZBPI. Pain severity was
highest at the time of recruitment and decreased signiﬁcantly
during the ﬁrst 7 days in the incident cases (mean changes of
1.50, 1.56, and 1.78 in least, average, and current pain,
respectively), or the ﬁrst 30 days in the prevalent HZ cases (mean
changes of 1.42, 1.73, and 1.88 in least, average, and current
pain, respectively). A further decrease in the pain severity scores
was observed by 180 days. By the end of the 180-day follow-up
period, 24.1% of responders reported still having HZ-related pain.
The impact of zoster-associated pain on patient daily activities is
shown in Figure 2. Zoster-associated pain was reported to have a
signiﬁcant impact on almost all dimensions measured by the ZBPI;
however patient mood and enjoyment of life were affected the most.
Figure 3 summarizes the mean EQ-5D score over time. HZ
incidence resulted in a signiﬁcant reduction in patient QoL with the
mean(SD)EQ-5Dscoredecreasingfrom0.91(0.12)priortoHZto0.65
(0.16) after HZ onset. QoL improved thereafter, however the impact
ofHZonpatientQoLremainedsigniﬁcantuntil180daysof follow-up,
as indicatedbythestatisticallylowerEQ-5Dscorescomparedtoprior
to the onset of HZ. A similar trend was observed when looking at the
subgroupsof incidentandprevalentcases.Of note,themean(SD)EQ-
5D score in the prevalent cases was consistently lower than that of
the incident cases throughout the study period.
HZ-related HCRU after the shingles episode and during the 180-
dayobservationperiodissummarizedinTable4.Themostcommonly
utilized type of healthcare resource was visits to a primary care
physician’s ofﬁce (98.7% of patients), followed by visits to a specialist
(55.0%), hospitalizations (32.5%), visits to the emergency room
(17.9%), and visits to a physiotherapist (15.2%). Among those who
visited the primary care physician’s ofﬁce, patients visited an average
of 7.0 times. Among those who required hospitalization, patients
stayed in the hospital for an average of 8.9 days.
Table 2
Multivariate analysis assessing predictors of the herpes zoster severity-of-illness score (HZ-SOI)a
HZ-SOI0–180 days HZ-SOI0–30 days HZ-SOI30–90 days HZ-SOI90–180 days
Estimate SE p-Value Estimate SE p-Value Estimate SE p-Value Estimate SE p-Value
Age, years
50–59 Ref - - Ref. - - Ref. - - Ref. - -
60–69 39.1 66.5 0.558 2.6 12.2 0.833 20.4 24.9 0.414 16.1 40.8 0.694
>70 159.1 79.6 0.048 12.8 14.6 0.382 63.0 29.7 0.036 83.2 49.1 0.093
Cohort
Incidence cases Ref. - - Ref. - - Ref. - - Ref. - -
Prevalent cases 206.6 63.6 0.002 107.6 11.5 <0.001 88.1 23.8 <0.001 10.9 39.1 0.781
Worst pain score at rash onset
Per unit of pain (0–10) 22.8 13.7 0.099 7.7 2.5 0.003 5.3 5.1 0.300 9.7 8.4 0.251
Number of lesions in primary/adjacent dermatomes
1–10 Ref. - - Ref. - - Ref. - - Ref. - -
11–20 99.3 80.6 0.220 8.3 15.1 0.584 40.6 30.3 0.182 50.4 49.4 0.309
21–50 47.3 73.0 0.518 1.5 13.4 0.913 4.5 27.2 0.869 41.3 44.9 0.360
>50 151.8 112.6 0.180 22.5 20.2 0.268 43.8 42.0 0.299 85.5 69.7 0.222
Antiviral medication
No Ref. - - Ref. - - Ref. - - Ref. - -
Yes 344.2 119.5 0.005 53.4 25.0 0.036 118.4 44.8 0.009 172.4 72.6 0.019
Immune status
Normal Ref. - - Ref. - - Ref. - - Ref. - -
Impairedb 25.0 100.2 0.803 7.9 18.0 0.660 3.8 37.2 0.918 13.3 61.9 0.831
SE, standard error; Ref., reference.
a The saturated models are shown for more information on the impact of possible predictors. Similar results were obtained upon excluding the non-signiﬁcant covariates
(number of lesions, immune status) from the models.
b Deﬁned as use of oral corticosteroids, immunosuppressive therapy, therapy for organ transplant, or chemotherapy for solid tumor, presence of invasive cancer, HIV/AIDS
infections, or hematologic malignancy, or low neutrophil or CD4 count.
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To our knowledge, this is the ﬁrst study prospectively assessing
the HZ burden of illness in South Korea. Overall, signiﬁcant HZ-
associated pain was observed over 180 days of follow-up after
disease onset, which affected all activities of daily living and was
associated with decreased QoL and increased HCRU.
Sixty-ﬁve percent of the patients experienced moderate to
severe pain (worst pain of 3 on a 0–10 scale) during the
prodromal phase, while 38.4% developed post-herpetic neuralgia,
a debilitating and long-lasting pain. The higher incidence of post-
herpetic neuralgia relative to that observed in other prospective
studies in Canada and Thailand,25,26 is probably due to the
inclusion of both prevalent and incident cases of HZ (post-
herpetic neuralgia incidence of 46.7% and 19.6%, respectively). In
accordance, severity of illness was also signiﬁcantly higher in
prevalent cases. Alternatively, the participation of specialists may
have resulted in the recruitment of more severe cases of HZ.Figure 2. Interference of zoster-associated pain with daily activities. The level of
interference was rated on a scale from 0 (no interference) to 10 (complete
interference).Consistent with a previous study in Canada,21 higher acute pain
severity and older age were identiﬁed as predictors of greater
severity of illness, while the use of antiviral medications was
associated with decreased severity and duration of HZ-associated
pain.
In light of the increasing proportion of the elderly population in
South Korea (by 2050 South Korea is expected to be the world’s
second oldest population, with 35% of its population over 65 years
of age)27–29 and the fact that the HZ prevalence in South Korea is
highest in individuals in their seventies,1 the ﬁnding that greater
HZ severity of illness was observed in older patients is highly
important. Interestingly, older age predicted higher HZ-SOI only in
the sub-acute and chronic phases, suggesting that younger and
older cases are as likely to experience a signiﬁcant burden of illness
in the acute phase and that the effect of HZ is more chronic in
elderly patients. This is in agreement with the fact that older cases
are at a signiﬁcantly higher risk of developing post-herpetic
neuralgia.30–33Figure 3. EuroQoL score over time by prevalent and incident cases.
*Statistically signiﬁcant changes (p < 0.05) in EQ-5D score from before the herpes
zoster episode.
Table 3
Zoster-associated pain over timea
Pain parameter Visit (day) Cohort Total cohort (N=151)
Prevalent cases (n=105) Incident cases (n=46)
n Pain Change from baseline n Pain Change from baseline n Pain Change from baseline
Mean (SD) Mean (SD) p-Valueb Mean (SD) Mean (SD) p-Valueb Mean (SD) Mean (SD) p-Valueb
Least pain in last 24 h 0 104 2.77 (2.47) NA NA 46 3.07 (2.69) NA NA 150 2.86 (2.54) NA NA
7 - - - - 18 1.61 (1.88) 1.50 (1.58) 0.001 18 1.61 (1.88) 1.50 (1.58) 0.001
14 - - - - 27 1.56 (1.89) 1.48 (3.24) 0.025 27 1.56 (1.89) 1.48 (3.24) 0.025
21 - - - - 28 1.29 (1.65) 1.64 (3.15) 0.010 28 1.29 (1.65) 1.64 (3.15) 0.010
30 93 1.27 (1.99) 1.42 (2.54) <0.001 40 1.10 (1.79) 2.08 (3.16) <0.001 133 1.22 (1.93) 1.62 (2.75) <0.001
60 91 1.18 (1.91) 1.38 (2.79) <0.001 39 0.64 (1.27) 2.49 (2.92) <0.001 130 1.02 (1.76) 1.71 (2.86) <0.001
90 93 1.11 (2.10) 1.42 (3.00) <0.001 40 0.20 (0.72) 2.90 (2.82) <0.001 133 0.83 (1.85) 1.87 (3.01) <0.001
120 92 1.01 (1.91) 1.52 (2.91) <0.001 39 0.18 (0.68) 2.95 (2.83) <0.001 131 0.76 (1.68) 1.95 (2.95) <0.001
150 94 0.95 (2.04) 1.65 (2.78) <0.001 39 0.10 (0.45) 3.00 (2.80) <0.001 133 0.70 (1.78) 2.05 (2.84) <0.001
180 94 0.73 (1.71) 1.86 (2.68) <0.001 39 0.15 (0.71) 3.00 (2.86) <0.001 133 0.56 (1.51) 2.20 (2.78) <0.001
Average pain in last 24 h 0 104 3.94 (2.54) NA NA 46 4.74 (2.45) NA NA 150 4.19 (2.53) NA NA
7 - - - - 18 3.06 (2.13) 1.56 (1.79) 0.002 18 3.06 (2.13) 1.56 (1.79) 0.002
14 - - - - 27 3.11 (2.53) 1.70 (3.34) 0.013 27 3.11 (2.53) 1.70 (3.34) 0.013
21 - - - - 28 2.14 (2.24) 2.54 (3.21) <0.001 28 2.14 (2.24) 2.54 (3.21) <0.001
30 93 2.19 (2.60) 1.73 (2.76) <0.001 40 1.95 (2.03) 2.90 (3.03) <0.001 133 2.12 (2.44) 2.08 (2.88) <0.001
60 91 1.75 (2.46) 2.02 (2.75) <0.001 39 0.97 (1.78) 3.85 (2.86) <0.001 130 1.52 (2.30) 2.57 (2.90) <0.001
90 93 1.89 (2.60) 1.90 (3.07) <0.001 40 0.70 (1.22) 4.10 (2.55) <0.001 133 1.53 (2.33) 2.57 (3.08) <0.001
120 92 1.59 (2.41) 2.21 (3.27) <0.001 39 0.41 (1.02) 4.41 (2.61) <0.001 131 1.24 (2.16) 2.87 (3.24) <0.001
150 94 1.62 (2.57) 2.20 (3.13) <0.001 39 0.54 (1.19) 4.23 (2.41) <0.001 133 1.30 (2.30) 2.80 (3.07) <0.001
180 94 1.21 (2.25) 2.63 (2.97) <0.001 39 0.21 (0.73) 4.64 (2.64) <0.001 133 0.92 (1.98) 3.23 (3.01) <0.001
Current pain 0 104 3.61 (2.49) NA NA 46 4.09 (2.51) NA NA 150 3.75 (2.50) NA NA
7 - - - - 18 2.61 (2.23) 1.78 (2.05) 0.002 18 2.61 (2.23) 1.78 (2.05) 0.002
14 - - - - 27 2.81 (3.01) 1.22 (3.68) 0.097 27 2.81 (3.01) 1.22 (3.68) 0.097
21 - - - - 28 1.89 (2.39) 2.00 (3.13) 0.002 28 1.89 (2.39) 2.00 (3.13) 0.002
30 93 1.69 (2.32) 1.88 (2.68) <0.001 39 1.33 (1.99) 2.79 (2.66) <0.001 132 1.58 (2.29) 2.15 (2.70) <0.001
60 91 1.21 (2.30) 2.23 (2.74) <0.001 39 0.90 (1.50) 3.13 (2.61) <0.001 130 1.12 (2.09) 2.50 (2.72) <0.001
90 93 1.63 (2.64) 1.79 (3.11) <0.001 40 0.65 (1.39) 3.38 (2.71) <0.001 133 1.34 (2.37) 2.27 (3.07) <0.001
120 91 1.12 (2.19) 2.33 (3.02) <0.001 39 0.33 (0.84) 3.69 (2.58) <0.001 130 0.88 (1.92) 2.74 (2.95) <0.001
150 94 1.34 (2.63) 2.14 (3.22) <0.001 39 0.54 (1.25) 3.46 (2.79) <0.001 133 1.11 (2.33) 2.53 (3.14) <0.001
180 94 1.11 (2.27) 2.40 (2.92) <0.001 39 0.26 (0.91) 3.79 (2.75) <0.001 133 0.86 (2.01) 2.81 (2.93) <0.001
SD, standard deviation; NA, not applicable.
a The level of pain was rated on a scale from 0 (no pain) to 10 (pain as bad as you can imagine).
b p-Value was assessed with the one-sample t-test.
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Table 4
Herpes zoster-associated healthcare resource utilization (HCRU) from rash onset to end of study
Type of healthcare resource Cohort Total cohort (n = 151)
Prevalent cases (n = 105) Incident cases (n = 46)
n (%) Mean number  SDa n (%) Mean number  SDa n (%) Mean number  SDa
Visit to primary care doctor’s ofﬁce 104 (99.0) 8.0  8.2 45 (97.8) 4.7  3.4 149 (98.7) 7.0  7.2
Visit to a specialistb 61 (58.1) 5.5  9.1 22 (47.8) 3.7  3.8 83 (55.0) 5.0  8.0
Hospitalization 34 (32.4) 8.6  9.9c 15 (32.6) 9.4  8.2c 49 (32.5) 8.9  9.3c
Visit to emergency room 18 (17.1) 1.3  0.6 9 (19.6) 1.3  0.5 27 (17.9) 1.3  0.5
Visit to a physiotherapist/rehabilitation 16 (15.2) 7.0  14.3 7 (15.2) 9.3  11.6 23 (15.2) 7.6  13.4
Admission to long-term care facility 0 (0.0) NA 2 (4.3) 3.5  3.5d 2 (1.3) 3.5  3.5d
Nursing services 1 (1.0) 9.0 (NC) 0 (0.0) NA 1 (0.7) 9.0 (NC)
Ambulance service 2 (1.9) 1.0  0.0 0 (0.0) NA 2 (1.3) 1.0  0.0
Psychiatrist/psychologist/counselor 2 (1.9) 1.0  0.0 0 (0.0) NA 2 (1.3) 1.0  0.0
NC, not calculable; NA, not applicable.
a Among patients who used the respective healthcare resource.
b Except a physician or a dermatologist.
c Number of days spent in hospital; median of 6.0 days, 8.0 days, and 6.0 days for prevalent cases, incident cases, and total cohort, respectively.
d Number of days spent in long-term care facility.
H. Song et al. / International Journal of Infectious Diseases 20 (2014) 23–30 29Despite the fact that the use of antiviral medications was
associated with signiﬁcantly lower HZ-associated pain severity
and duration, regardless of the phase of the HZ illness, only 52.3%
were treated with antivirals at enrolment. This proportion is lower
compared to that observed in Canada (88.9%), the USA (85.0%),
Thailand (85.6%), and Spain (91.5%);25,26,34,35 however this is
probably due to the shorter time elapsed from symptom onset to
enrolment in those studies compared to the current study. In
support of this, antiviral medications were used in 95.6% of the
incident cases included in our study.
A previous study showed that impaired immune status is
associated with greater HZ severity of illness;20 however we did
not ﬁnd a signiﬁcant association, possibly due to the small number
of immunocompromised patients in our study.
HZ-associated pain signiﬁcantly interfered with all activities of
daily living (ADL), particularly mood, enjoyment of life, general
activities, and sleep; the highest level of interference was observed
at baseline when the HZ-associated pain was maximal. The mean
EQ-5D score, assessing patient mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression, also paralleled the ADL
impact of HZ, being lowest at baseline and increasing thereafter. In
line with these ﬁndings, previous studies have also shown that
acute HZ pain and discomfort has a signiﬁcant negative impact on
functional status and patient QoL.34 In accordance with the severe
burden of illness, signiﬁcant HCRU was associated with the
management of HZ, including visits to the primary care doctor, a
specialist, or a physiotherapist, hospitalizations, and visits to the
emergency department.
Several limitations of this study are worth noting. The study
recruited prevalent cases who had already endured at least 7 days
of illness since rash onset, which may have led to recall bias in the
evaluation of their pain, QoL, and HCRU prior to or at rash onset.
Furthermore, misclassiﬁcation of disease cannot be ruled out,
given the fact that laboratory conﬁrmation of HZ infection was not
required for the patient to be eligible for the study. Finally, our
study included patients who sought care for HZ, which may have
resulted in the inclusion of slightly more severe cases of HZ than
those found in the general population. Moreover, prevalent cases
may over-represent the group of patients requiring greater
medical care compared to the general population.
In conclusion, the present study showed that HZ in South Korea
is associated with signiﬁcant morbidity and healthcare utilization
and reduced quality of life. Patients older than 70 years of age are
particularly at an increased risk of severe and long-lasting pain that
often affects health-related quality of life and daily activities. Incountries that have experienced rapid development and sustained
economic growth, populations now have a better life expectancy
and therefore the number of HZ and post-herpetic neuralgia cases
is expected to increase in the coming years due to the steady
increase in the elderly population. Such changes in the population
demographics require modiﬁcations in the allocation of resources
to reduce the burden of vaccine-preventable illnesses such as
herpes zoster among those at the highest risk, namely patients 50
years of age.
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